Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand

AIDS

Volumn 29, Issue 18, 2015, Pages 2497-2507

  Lallemant, Marc ^a,b,c   Coeur, Sophie Le ^a,b,c,d   Sirirungsi, Wasna ^c   Cressey, Tim R ^a,b,c   Ngo Giang Huong, Nicole ^a,b,c   Traisathit, Patrinee ^c   Klinbuayaem, Virat ^e   Sabsanong, Prapan ^e   Kanjanavikai, Prateep ^f   Jourdain, Gonzague ^a,b,c   McIntosh, Kenneth ^b,g   Koetsawang, Suporn ^h  

^a Institute of research for development Thailand   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

^f Banglamung Hospital   (Thailand)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; Clinical trial; HIV; Prevention of mother tochild transmission; Thailand

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; LAMIVUDINE; NEVIRAPINE; PLACEBO; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BIRTH WEIGHT; CD4+ T LYMPHOCYTE; CELL COUNT; CESAREAN SECTION; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTESTINE OBSTRUCTION; LABOR ONSET; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; NEWBORN DEATH; PERINATAL INFECTION; PHASE 3 CLINICAL TRIAL; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SMALL FOR DATE INFANT; STILLBIRTH; THAILAND; VERTICAL TRANSMISSION; VERY LOW BIRTH WEIGHT; VIRUS LOAD; BLOOD; CHEMOPROPHYLAXIS; CLINICAL TRIAL; HIV INFECTIONS; INFANT; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; PLACEBOS; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; THAILAND; TREATMENT OUTCOME; YOUNG ADULT; ZIDOVUDINE;

EID: 84947868974     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000865     Document Type: Article

References (36)

1. Department of Disease Control. National antiretroviral treatment guidelines 2006/2007. Thailand: Ministry of Public Health; 2007.
2. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach. Geneva: World Health Organization; 2006.
3. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Recommendations for a public health approach. 2010 version. Geneva: World Health Organization; 2010.
4. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228.
5. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanu-wong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
6. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
7. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363:1499-1509.
8. Palmer S, Boltz VF, Chow JY, Martinson NA, McIntyre JA, Gray GE, et al. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antivir Ther 2012; 17:327-336.
9. British Medical Association. British Medical Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Medicine 2014; 15:1-77.
10. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, Frenkel L, Britto P, Roongpisuthipong A, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevir-apine. Clin Infect Dis 2012; 54:285-293.
11. Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20:1281-1288.
12. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
13. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032-1035.
14. Zuckerman AJ. Hepatitis viruses. In: Baron S, ed. Medical microbiology, 4th ed. Galveston, TX: The University of Texas Medical Branch at Galveston; 1996. pp. 849-863 [chapter 70].
15. Phanuphak N, Lolekha R, Chokephaibulkit K, Voramongkol N, Boonsuk S, Limtrakul A, et al. Thai national guidelines for the prevention of mother-to-child transmission of HIV: March 2010. Asian Biomedicine 2010; 4:529-540.
16. Ngo-Giang-Huong N, Khamduang W, Leurent B, Collins I, Nantasen I, Leechanachai P, et al. Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settings. J Acquir Immune Defic Syndr 2008; 49:465-471.
17. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1246-1247.
18. Division of AIDS table for grading the severity of adult and pediatric adverse events Version 1.0, December, 2004; clarification August 2009. http://rsc.tech-res.com/Document/safety andpharmacovigilance/Table-for-Grading-Severity-of-Adult- Pediatric-Adverse-Events.pdf. 2004.
19. Tongsong T, Simaraks S, Sirivatanapa P, Sudasna J, Wanapirak C, Kunavikatikul C, et al. Study of intrauterine growth from birthweight at Maharaj Nakhon Chiang Mai Hospital. J Med Assoc Thai 1993; 76:482-486.
20. Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, et al. Lopinavir/ritonavir monotherapy as a nucleo-side analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial. Clin Infect Dis 2013; 57:891-902.
21. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22:289-299.
22. Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpa-nichkul R, Sabsanong P, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010; 24:2193-2200.
23. Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366:2368-2379.
24. Gingelmaier A, Kurowski M, Kastner R, Eberle J, Mylonas I, Belohradsky BH, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20:1737-1743.
25. Ivanovic J, Nicastri E, Anceschi MM, Ascenzi P, Signore F, Pisani G, et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res 2009; 7:620-625.
26. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16:1149-1167.
27. O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993; 168:1510-1516.
28. Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991; 163:226-232.
29. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-1629.
30. Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL, et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:232-236.
31. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
32. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neo-nates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368-374.
33. Kesho Bora Study G, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
34. Fowler MG, Quin M, Fiscus SA, Currier JS, Makanani B, Martinson F, et al. PROMISE: Efficacy and Safety of 2 strategies to prevent Perinatal HIV Transmission. CROI 2015, 31LB 2015.
35. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States; 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. [Accessed 4 June 2015]
36. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.